Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation

被引:65
|
作者
Bahit, M. Cecilia [1 ]
Lopes, Renato D. [2 ]
Wojdyla, Daniel M. [2 ]
Held, Claes [3 ]
Hanna, Michael [4 ]
Vinereanu, Dragos [5 ]
Hylek, Elaine M. [6 ]
Verheugt, Freek [7 ]
Goto, Shinya [8 ]
Alexander, John H. [2 ]
Wallentin, Lars [3 ]
Granger, Christopher B. [2 ]
机构
[1] INECO, Neurociencias Orono Rosario, Santa Fe, NM, Argentina
[2] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA
[3] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden
[4] Bristol Myers Squibb, Princeton, NJ USA
[5] Univ Med & Pharm Carol Davila, Bucharest, Romania
[6] Boston Univ, Med Ctr, Boston, MA USA
[7] Onze Lieve Vrouwe Gasthuis OLVG, Heartctr, Amsterdam, Netherlands
[8] Tokai Univ, Sch Med, Isehara, Kanagawa, Japan
关键词
HEMORRHAGE; DABIGATRAN; THERAPY; STROKE; RISK;
D O I
10.1136/heartjnl-2016-309901
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective We describe the incidence, location and management of non-major bleeding, and assess the association between non-major bleeding and clinical outcomes in patients with atrial fibrillation (AF) receiving anticoagulation therapy enrolled in Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE). Methods We included patients who received >= 1 dose of study drug (n= 18 140). Non-major bleeding was defined as the first bleeding event considered to be clinically relevant non-major (CRNM) or minor bleeding, and not preceded by a major bleeding event. Results Non-major bleeding was three times more common than major bleeding (12.1% vs 3.8%). Like major bleeding, non-major bleeding was less frequent with apixaban (6.4 per 100 patient-years) than warfarin (9.4 per 100 patient-years) (adjusted HR 0.69, 95% CI 0.63 to 0.75). The most frequent sites of non-major bleeding were haematuria (16.4%), epistaxis (14.8%), gastrointestinal (13.3%), haematoma (11.5%) and bruising/ecchymosis (10.1%). Medical or surgical intervention was similar among patients with non-major bleeding on warfarin versus apixaban (24.7% vs 24.5%). A change in antithrombotic therapy (58.6% vs 50.0%) and permanent study drug discontinuation (5.1% (61) vs 3.6% (30), p=0.10) was numerically higher with warfarin than apixaban. CRNM bleeding was independently associated with an increased risk of overall death (adjusted HR 1.70, 95% CI 1.32 to 2.18) and subsequent major bleeding (adjusted HR 2.18, 95% CI 1.56 to 3.04). Conclusions In ARISTOTLE, non-major bleeding was common and substantially less frequent with apixaban than with warfarin. CRNM bleeding was independently associated with a higher risk of death and subsequent major bleeding. Our results highlight the importance of any severity of bleeding in patients with AF treated with anticoagulation therapy and suggest that non-major bleeding, including minor bleeding, might not be minor.
引用
收藏
页码:623 / 628
页数:6
相关论文
共 50 条
  • [41] BODY MASS INDEX AND OUTCOMES WITH APIXABAN VERSUS WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION IN THE ARISTOTLE (APIXABAN FOR REDUCTION IN STROKE AND OTHER THROMBOEMBOLIC EVENTS IN ATRIAL FIBRILLATION) TRIAL
    Sandhu, Roopinder K.
    Ezekowitz, Justin
    Andersson, Ulrika
    Alexander, John
    Granger, Christopher
    Halvorsen, Sigrun
    Hanna, Michael
    Hijazi, Ziad
    Jansky, Petr
    Lopes, Renato
    Wallentin, Lars
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) : A284 - A284
  • [42] Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin The Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin k Antagonist Treatment (AVERROES) Trial
    Flaker, Greg C.
    Eikelboom, John W.
    Shestakovska, Olga
    Connolly, Stuart J.
    Kaatz, Scott
    Budaj, Andrzej
    Husted, Steen
    Yusuf, Salim
    Lip, Gregory Y. H.
    Hart, Robert G.
    [J]. STROKE, 2012, 43 (12) : 3291 - +
  • [43] REAL-WORLD COMPARISON OF MAJOR BLEEDING RISK AMONG UNTREATED NON-VALVULAR ATRIAL FIBRILLATION PATIENTS AND THOSE INITIATING APIXABAN, DABIGATRAN, RIVAROXABAN, OR WARFARIN
    Amin, Alpesh
    Keshishian, Allison
    Xie, Lin
    Baser, Onur
    Price, Kwanza
    Vo, Lien
    Mardekian, Jack
    Mendoza, Mario
    Singhal, Shalabh
    Patel, Chad
    Odell, Kevin
    Trocio, Jeffrey
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 668 - 668
  • [44] Real-world comparison of major bleeding and associated costs among treatment-naive non-valvular atrial fibrillation patients initiating apixaban or warfarin
    Amin, A.
    Keshishian, A. V.
    Xie, L.
    Baser, O.
    Price, K.
    Vo, L.
    Mardekian, J.
    Mendoza, M.
    Singhal, S.
    Patel, C.
    Odell, K.
    Trocio, J.
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 : 506 - 506
  • [45] Real-world comparison of major bleeding and associated costs among treatment-naive non-valvular atrial fibrillation patients initiating apixaban or warfarin
    Amin, Alpesh
    Keshishian, Allison
    Xie, Lin
    Baser, Onur
    Price, Kwanza
    Vo, Lien
    Mardekian, Jack
    Mendoza, Mario
    Singhal, Shalabh
    Patel, Chad
    Odell, Kevin
    Trocio, Jeffrey
    [J]. PHARMACOTHERAPY, 2016, 36 (12): : E214 - E214
  • [47] Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
    Yao, Xiaoxi
    Abraham, Neena S.
    Sangaralingham, Lindsey R.
    Bellolio, M. Fernanda
    McBane, Robert D.
    Shah, Nilay D.
    Noseworthy, Peter A.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (06):
  • [49] BLEEDING RISK AMONG JAPANESE NON-VALVULAR ATRIAL FIBRILLATION PATIENTS INITIATED ON APIXABAN, DABIGATRAN, RIVAROXABAN OR WARFARIN IN THE REAL WORLD
    Wang, Feng
    Murata, Tatsunori
    Izumi, Naoko
    Kida, Makoto
    Horblyuk, Ruslan
    Terayama, Yasuo
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 443 - 443
  • [50] ARISTOTLE reveals superiority of apixaban over warfarin in patients with atrial fibrillation
    Bryony M. Mearns
    [J]. Nature Reviews Cardiology, 2011, 8 (11) : 607 - 607